Price
CHART BY
Frequently asked questions
What is Argenx's market capitalization?
The market capitalization of Argenx is $37.95B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Argenx?
Argenx's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.361. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Argenx's stock?
Currently, 31 analysts cover Argenx's stock, with a consensus target price of $662.08. Analyst ratings provide insights into the stock's expected performance.
What is Argenx's revenue over the trailing twelve months?
Over the trailing twelve months, Argenx reported a revenue of $1.55B.
What is the EBITDA for Argenx?
Argenx's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$273.77M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Argenx?
Argenx has a free cash flow of -$140.89M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Argenx have, and what sector and industry does it belong to?
Argenx employs approximately 1,148 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Other industry.
What is the free float of Argenx's shares?
The free float of Argenx is 60.33M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $37.95B
- EPS (TTM)
- -$3.361
- Free Float
- 60.33M
- Revenue (TTM)
- $1.55B
- EBITDA (TTM)
- -$273.77M
- Free Cashflow (TTM)
- -$140.89M
Pricing
- 1D span
- $622.02$631.26
- 52W span
- $347.63$643.33
Analyst Ratings
The price target is $662.08 and the stock is covered by 31 analysts.
Buy
27
Hold
4
Sell
0
Information
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
- Employees
- 1,148
- Industries
- Pharmaceuticals: Other
- Sector
- Health Care
Identifier
- ISIN
- NL0010832176
- Primary Ticker
- ARGX